Most cited papers in Biosimilars and Bioanalytical Methods
What are the most cited papers in Biosimilars and Bioanalytical Methods?
The most cited paper in Biosimilars and Bioanalytical Methods is "EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update" (Josef S Smolen et al., 2017), with 5,808 citations. Next come "The price of innovation: new estimates of drug development costs" (4,325) and "Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial" (4,190).
Showing 50 of 100 papers. Every paper with more than 598 citations is listed.
| # | Paper | ||
|---|---|---|---|
| 1 | EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update Josef S Smolen et al. · Annals of the Rheumatic Diseases | 6 Mar 2017 | 5,808 |
| 2 | The price of innovation: new estimates of drug development costs Joseph A. DiMasi, Ronald W. Hansen, Henry G. Grabowski · Journal of Health Economics | 28 Feb 2003 | 4,325 |
| 3 | Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial Stephen B. Hanauer, Brian G. Feagan, Gary R. Lichtenstein et al. · The Lancet | May 2002 | 4,190 |
| 4 | Can the pharmaceutical industry reduce attrition rates? Ismail Kola, John Richard Landis · Nature Reviews Drug Discovery | 30 Jul 2004 | 4,181 |
| 5 | A rapid method for the isolation of functional thymus‐derived murine lymphocytes Michael H. Julius, Elizabeth Simpson, L A Herzenberg · European Journal of Immunology | Oct 1973 | 4,167 |
| 6 | Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis Paul J. Rutgeerts, William J. Sandborn, Brian G. Feagan et al. · New England Journal of Medicine | 7 Dec 2005 | 3,927 |
| 7 | Optimal two-stage designs for phase II clinical trials Richard M Simon · Controlled Clinical Trials | Mar 1989 | 3,673 |
| 8 | Innovation in the pharmaceutical industry: New estimates of R&D costs Joseph A. DiMasi, Henry G. Grabowski, Ronald W. Hansen · Journal of Health Economics | 13 Feb 2016 | 3,382 |
| 9 | A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease Stephan R. Targan, Stephen B. Hanauer, Sander J. H. van Deventer et al. · New England Journal of Medicine | 9 Oct 1997 | 3,171 |
| 10 | Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease Jean‐Frédéric Colombel, William J. Sandborn, Walter Reinisch et al. · New England Journal of Medicine | 14 Apr 2010 | 3,137 |
| 11 | EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update Josef S Smolen et al. · Annals of the Rheumatic Diseases | 22 Jan 2020 | 2,807 |
| 12 | Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and Malignancies Tim Bongartz, Alex J. Sutton, Michael J. Sweeting et al. · JAMA | 16 May 2006 | 2,486 |
| 13 | A pharmacokinetic analysis program (multi) for microcomputer. Kiyoshi Yamaoka, Yusuke Tanigawara, Terumichi Nakagawa et al. · Journal of Pharmacobio-Dynamics | 1981 | 2,459 |
| 14 | Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn’s Disease: The CHARM Trial Jean–Frédéric Colombel, William J. Sandborn, Paul J. Rutgeerts et al. · Gastroenterology | 30 Nov 2006 | 2,263 |
| 15 | Development of therapeutic antibodies for the treatment of diseases Ruei‐Min Lu, Yu‐Chyi Hwang, I-Ju Liu et al. · Journal of Biomedical Science | 2020 | 2,178 |
| 16 | Normalization of Hemoglobin Level in Patients with Chronic Kidney Disease and Anemia Tilman Bernhard Drüeke, Francesco Locatelli, Naomi Clyne et al. · New England Journal of Medicine | 15 Nov 2006 | 2,113 |
| 17 | A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease Marc A. Pfeffer, Emmanuel A. Burdmann, Chao Yin Chen et al. · New England Journal of Medicine | 30 Oct 2009 | 2,110 |
| 18 | Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease Filip Baert, Maja Noman, Severine A.R.A. Vermeire et al. · New England Journal of Medicine | 12 Feb 2003 | 2,029 |
| 19 | EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update Josef S Smolen et al. · Annals of the Rheumatic Diseases | 10 Nov 2022 | 1,921 |
| 20 | 2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis Jasvinder A. Singh et al. · Arthritis Care & Research | 2 Apr 2012 | 1,806 |
| 21 | EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update Josef S Smolen et al. · Annals of the Rheumatic Diseases | 25 Oct 2013 | 1,768 |
| 22 | Bioanalytical Method Validation—A Revisit with a Decade of Progress Vinod P. Shah, Kamal K. Midha, John W. A. Findlay et al. · Pharmaceutical Research | Dec 2000 | 1,577 |
| 23 | American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease‐modifying antirheumatic drugs in rheumatoid arthritis Kenneth G. Saag et al. · Arthritis Care & Research | 30 May 2008 | 1,495 |
| 24 | Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab Jeffrey S. Weber, Katharina Charlotte Kähler, Axel Hauschild · Journal of Clinical Oncology | 22 May 2012 | 1,433 |
| 25 | Impact of high-throughput screening in biomedical research Ricardo Macarrón, Martyn N. Banks, Dejan Bojanic et al. · Nature Reviews Drug Discovery | Mar 2011 | 1,406 |
| 26 | Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework David R. Cook, Dearg S. Brown, Robert Alexander et al. · Nature Reviews Drug Discovery | 16 May 2014 | 1,376 |
| 27 | Pure Red-Cell Aplasia and Antierythropoietin Antibodies in Patients Treated with Recombinant Erythropoietin Nicole Casadevall, Joelle Nataf, B Viron et al. · New England Journal of Medicine | 14 Feb 2002 | 1,248 |
| 28 | Molecular imaging in drug development Jürgen K. Willmann, Nicholas van Bruggen, Ludger M. Dinkelborg et al. · Nature Reviews Drug Discovery | Jul 2008 | 1,170 |
| 29 | History of Erythropoiesis-Stimulating Agents, the Development of Biosimilars, and the Future of Anemia Treatment in Nephrology Kamyar Kalantar‐Zadeh · American Journal of Nephrology | 2017 | 1,149 |
| 30 | Certolizumab Pegol for the Treatment of Crohn's Disease William J. Sandborn, Brian G. Feagan, Simeon Stoinov et al. · New England Journal of Medicine | 18 Jul 2007 | 1,146 |
| 31 | Bad Bugs Need Drugs: An Update on the Development Pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America George H. Talbot, John S. Bradley, John Ernest Edwards et al. · Clinical Infectious Diseases | Feb 2006 | 1,109 |
| 32 | Efficacy and safety of retreatment with anti–tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease Paul J. Rutgeerts, Geert D’Haens, Stephan R. Targan et al. · Gastroenterology | Oct 1999 | 1,096 |
| 33 | The Economics of Reproducibility in Preclinical Research Leonard P. Freedman, Iain Cockburn, Timothy S. Simcoe · PLoS Biology | 9 Jun 2015 | 1,096 |
| 34 | Treatment of Rheumatoid Arthritis by Selective Inhibition of T-Cell Activation with Fusion Protein CTLA4Ig Joel M. Kremer, René Westhovens, Marc Léon et al. · New England Journal of Medicine | 12 Nov 2003 | 1,065 |
| 35 | Maintenance Therapy with Certolizumab Pegol for Crohn's Disease Stefan Schreiber, Mani Khaliq-Kareemi, Ian Craig Lawrance et al. · New England Journal of Medicine | 18 Jul 2007 | 1,050 |
| 36 | Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial William J. Sandborn, Stephen B. Hanauer, Paul Rutgeerts et al. · Gut | 13 Feb 2007 | 1,043 |
| 37 | Artificial Intelligence in Pharmaceutical Technology and Drug Delivery Design Lalitkumar K. Vora, Amol Dilip Gholap, Keshava L. Jetha et al. · Pharmaceutics | 10 Jul 2023 | 1,041 |
| 38 | Biopharmaceutical benchmarks 2014 Gary Walsh · Nature Biotechnology | Oct 2014 | 1,016 |
| 39 | Biopharmaceutical benchmarks 2018 Gary Walsh · Nature Biotechnology | Dec 2018 | 1,004 |
| 40 | Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist Barry Bresnihan, Jos� Maria Alvaro-Gracia, Mark Cobby et al. · Arthritis & Rheumatism | Dec 1998 | 978 |
| 41 | Adalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab William J. Sandborn, Paul J. Rutgeerts, Robert Enns et al. · Annals of Internal Medicine | 19 Jun 2007 | 963 |
| 42 | Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease Paul J. Rutgeerts, Brian G. Feagan, Gary R. Lichtenstein et al. · Gastroenterology | Feb 2004 | 952 |
| 43 | How many antibiotics are produced by the genus Streptomyces ? Milind Watve, Rashmi Tickoo, Maithili M. Jog et al. · Archives of Microbiology | Nov 2001 | 934 |
| 44 | The impact of aromatic ring count on compound developability – are too many aromatic rings a liability in drug design? Timothy J. Ritchie, Simon J. F. Macdonald · Drug Discovery Today | 2 Sep 2009 | 911 |
| 45 | Serious Infections and Mortality in Association With Therapies for Crohn’s Disease: TREAT Registry Gary R. Lichtenstein, Brian G. Feagan, Russell D. Cohen et al. · Clinical Gastroenterology and Hepatology | May 2006 | 911 |
| 46 | The safety profile of infliximab in patients with Crohn’s disease: The Mayo Clinic experience in 500 patients Jean‐Frédéric Colombel, Edward V. Loftus, William J. Tremaine et al. · Gastroenterology | 30 Dec 2003 | 909 |
| 47 | Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease Niels Vande Casteele, Marc Ferrante, Gert Van Assche et al. · Gastroenterology | 24 Feb 2015 | 888 |
| 48 | A community effort to assess and improve drug sensitivity prediction algorithms NCI DREAM Community et al. · Nature Biotechnology | Jun 2014 | 854 |
| 49 | Strategies and challenges for the next generation of therapeutic antibodies Alain Beck, Thierry Wurch, Christian Bailly et al. · Nature reviews. Immunology | 23 Apr 2010 | 847 |
| 50 | Pregnancy and Laboratory Studies Mina Abbassi-Ghanavati, Laura G. Greer, F. Gary Cunningham · Obstetrics and Gynecology | 21 Nov 2009 | 838 |
Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for a field when OpenAlex files it under one of the field's topics; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.